DEF 14A: Pieris Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting

Pieris Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on December 2, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Summary

• Pieris Pharmaceuticals will hold its 2024 annual meeting of stockholders on December 2, 2024, at 9:00 a.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of October 25, 2024, are eligible to vote.
• The meeting will address the election of two directors for three-year terms expiring in 2027, ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2024, and a non-binding advisory vote on executive compensation.
• The Board of Directors recommends voting for the election of the director nominees and for the approval of the other proposals.
• The proxy statement, notice, proxy card, and 2023 annual report are available at www.proxyvote.com.
• As of November 1, 2024, there were 1,324,240 shares of common stock outstanding.
• The board dissolved the Nominating and Corporate Governance Committee and the Science and Technology Committee effective September 30, 2024, to conserve cash resources.
• The company has adopted an incentive compensation recoupment policy applicable to executive officers.
• The company prohibits employees and directors from engaging in transactions that are designed to, or have the effect of, hedging or offsetting any decrease in the market value of our shares owned by such employees or directors.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the agenda and voting matters for the annual meeting. The sentiment is neutral, with a slight positive leaning due to the Board's recommendations and expressions of gratitude.

Positives

• The company is providing stockholders with multiple avenues to participate in the annual meeting, including virtual attendance and voting.
• The Board of Directors is actively engaged in risk oversight and has established committees to address specific areas of risk.
• The company has adopted an incentive compensation recoupment policy applicable to executive officers.
• The company prohibits employees and directors from engaging in transactions that are designed to, or have the effect of, hedging or offsetting any decrease in the market value of our shares owned by such employees or directors.

Negatives

• The company dissolved the Nominating and Corporate Governance Committee and the Science and Technology Committee effective September 30, 2024, to conserve cash resources, which may reduce board oversight in these areas.

Risks

• The division of the Board of Directors into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• The company's success depends on attracting and retaining talented individuals with an entrepreneurial mindset.
• The possibility of a change in control may exist and that the uncertainty and questions that it may raise among management could result in the departure or distraction of management personnel to the detriment of the Company and our stockholders.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance, but it outlines the business to be conducted at the annual meeting and the Board's recommendations.

Management Comments

• Stephen S. Yoder, President and Chief Executive Officer, expresses gratitude for stockholders' continued support and encourages attendance at the annual meeting.

Industry Context

As a smaller reporting company, Pieris Pharmaceuticals' executive compensation disclosure is less extensive than that of larger companies, which is typical in the biopharmaceutical industry.

Comparison to Industry Standards

• The company benchmarks its executive compensation program against a peer group of biopharmaceutical companies, which is a common practice in the industry.
• The company's director compensation policy provides for cash and equity-based compensation, which is consistent with industry standards.

Management Changes

Corporate Governance

Related Party Transactions

• On July 23, 2024, we entered into the Merger Agreement pursuant to which, subject to the terms and conditions thereof, Polo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of us, will merge with and into Palvella, with Palvella surviving as a wholly owned subsidiary of us, and the surviving corporation of the merger, which transaction is referred to herein as the Merger.
• In connection with the Merger, on July 23, 2024, BVF, which holds more than 5% of our voting securities, along with other investors, or the PIPE Investors, entered into the a securities purchase agreement, or the Purchase Agreement, with us, pursuant to which such PIPE Investors have agreed to subscribe for and purchase (either for cash or in exchange for the termination and cancellation of outstanding convertible notes issued by Palvella), and we have agreed to issue and sell to the PIPE Investors, an aggregate of approximately 3,154,241 of shares of our common stock at a price per share equal to $13.7299 multiplied by (x) 0.315478 divided by (y) the Exchange Ratio, as defined in the Merger Agreement and is estimated to be equal to approximately 0.315478222 shares of our common stock for each share of Palvella capital stock, (the Purchase Price), subject to adjustment as set forth in the Purchase Agreement, and/or in lieu of our common stock to certain purchasers who so choose, pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 2,592,585 shares of the combined company common stock at a purchase price per Pre-Funded Warrant equal to the Purchase Price, subject to adjustment as set forth in the Purchase Agreement, minus $0.001.
• BVF agreed to purchase shares pursuant to the Purchase Agreement and, together with its respective affiliates, is expected to be a beneficial owner of more than 5% of the outstanding shares of us following this PIPE financing.

Stakeholder Impact

• Stockholders have the opportunity to vote on key matters affecting the company's direction and governance.
• Executive officers are subject to an incentive compensation recoupment policy, aligning their interests with those of the company and stockholders.
• Employees are subject to a Corporate Code of Conduct and Ethics and Whistleblower Policy.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on December 2, 2024, and announce the voting results.

Key Dates

Keywords

annual meeting, proxy statement, directors, executive compensation, Ernst & Young, stockholders, corporate governance, Pieris Pharmaceuticals